The cellular immune response to respiratory syncytial virus (RSV) is important in both protection and immunopathogenesis. In contrast to HLA class I, HLA class II-restricted RSV-specific T-cell epitopes have not been identified. Here, we describe the generation and characterization of two human RSV-specific CD4؉ -T-cell clones (TCCs) associated with type 0-like cytokine profiles. TCC 1 was specific for the matrix protein and restricted over HLA-DPB1*1601, while TCC 2 was specific for the attachment protein G and restricted over either HLA-DPB1*0401 or -0402. Interestingly, the latter epitope is conserved in both RSV type A and B viruses. Given the high allele frequencies of HLA-DPB1*0401 and -0402 worldwide, this epitope could be widely recognized and boosted by recurrent RSV infections. Indeed, peptide stimulation of peripheral blood mononuclear cells from healthy adults resulted in the detection of specific responses in 8 of 13 donors. Additional G-specific TCCs were generated from three of these cultures, which recognized the identical (n ؍ 2) or almost identical (n ؍ 1) HLA-DP4-restricted epitope as TCC 2. No significant differences were found between the capacities of cell lines obtained from infants with severe (n ؍ 41) or mild (n ؍ 46) RSV lower respiratory tract infections to function as antigen-presenting cells to the G-specific TCCs, suggesting that the severity of RSV disease is not linked to the allelic frequency of HLA-DP4. In conclusion, we have identified an RSV G-specific human T helper cell epitope restricted by the widely expressed HLA class II alleles DPB1*0401 and -0402. Its putative role in protection and/or immunopathogenesis remains to be determined.
Respiratory syncytial virus (RSV), a member of the genusPneumovirus of the family Paramyxoviridae, is a major cause of severe lower respiratory tract disease in infants, immunocompromised individuals, and the elderly (7, 29). RSV infections cause yearly epidemics in the winter season of moderate climate zones and are most often associated with relatively mild upper respiratory tract infections (29). In general, specific immunity is insufficient for protection, and RSV infections continue to occur throughout life.At present, no licensed RSV vaccine is available. During vaccine trials in the 1960s, vaccination with a formalin-inactivated whole-virus preparation (FI-RSV) was found to predispose for enhanced clinical disease following natural infection with RSV (17). Although the exact mechanism of this apparently immunopathological phenomenon remains unclear, studies of both rodent and nonhuman primate models have suggested that a skewed RSV-specific T helper type 2 (Th2) response was a key factor in this process (11,23). Several studies have suggested that primary infections in young infants resulting in severe RSV bronchiolitis are also associated with Th2 responses (24, 28). However, in two other cohort studies of infants with either severe RSV bronchiolitis or relatively mild RSV upper respiratory tract infection, this observation was...